Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2018

17.11.2017 | Original Article

Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey

verfasst von: Vu Q. Nguyen, Jessica L. Mays, Marissa Lang, Yingxing Wu, Themistocles Dassopoulos, Miguel Regueiro, Alan Moss, Deborah D. Proctor, Dario Sorrentino

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Postoperative recurrence (POR) of Crohn’s disease (CD) is common. Guidelines on POR management have recently been issued, but clinical practice may vary.

Aims

To examine the current clinical practice of POR management in the USA

Methods

A web-based survey was sent to all members of the American Gastroenterological Association and the American College of Gastroenterology. The survey consisted of multiple-choice questions with clinical scenarios to assess how participants manage POR.

Results

A total of 189 responses were received from practices in 34 states. 44% of participants were from academic settings. The median number of CD patients seen each month was 20–30 patients per participant. The majority of participants considered smoking, prior intestinal surgery, penetrating disease, perianal fistula, early disease onset, and long extent of disease as high-risk factors for POR. To diagnose and grade endoscopic recurrence, 57% of participants used an endoscopic scoring system; 86% defined clinical recurrence using a combination of symptoms and endoscopic findings; and 79% of participants routinely performed colonoscopy after surgery. In high-risk patients, 65% offered medical prophylaxis—most often biologics and/or immunomodulators—immediately after surgery, while 34% offered medical prophylaxis regardless of the patient’s risk of POR. 64% of participants never stopped medical prophylaxis once initiated.

Conclusions

Most gastroenterologists routinely perform colonoscopy to guide POR management. The majority of these providers continue medical prophylaxis indefinitely regardless of subsequent endoscopic findings. Further research is needed to determine the risks and benefits of continuing versus deescalating therapy in patients with potentially surgically induced remission.
Literatur
5.
Zurück zum Zitat D’Haens G, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology. 2008;135:1123–1129.CrossRefPubMed D’Haens G, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology. 2008;135:1123–1129.CrossRefPubMed
8.
Zurück zum Zitat Sorrentino D, Terrosu G, Avellini C, Beltrami CA, Bresadola V, Toso F. Prevention of postoperative recurrence of Crohn’s disease by infliximab. Eur J Gastroenterol Hepatol. 2006;18:457–459.CrossRefPubMed Sorrentino D, Terrosu G, Avellini C, Beltrami CA, Bresadola V, Toso F. Prevention of postoperative recurrence of Crohn’s disease by infliximab. Eur J Gastroenterol Hepatol. 2006;18:457–459.CrossRefPubMed
9.
Zurück zum Zitat Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med. 2007;167:1804–1807.CrossRefPubMed Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med. 2007;167:1804–1807.CrossRefPubMed
10.
Zurück zum Zitat Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441–450.CrossRefPubMed Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441–450.CrossRefPubMed
18.
Zurück zum Zitat Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–963.CrossRefPubMed Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99:956–963.CrossRefPubMed
20.
Zurück zum Zitat Viscido A, Corrao G, Taddei G, Caprilli R. “Crohn’s disease activity index” is inaccurate to detect the post-operative recurrence in Crohn’s disease. A GISC study. Gruppo Italiano per lo Studio del Colon e del Retto. Ital J Gastroenterol Hepatol. 1999;31:274–279.PubMed Viscido A, Corrao G, Taddei G, Caprilli R. “Crohn’s disease activity index” is inaccurate to detect the post-operative recurrence in Crohn’s disease. A GISC study. Gruppo Italiano per lo Studio del Colon e del Retto. Ital J Gastroenterol Hepatol. 1999;31:274–279.PubMed
23.
Zurück zum Zitat Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP. The use of azathioprine in Crohn’s disease during pregnancy and in the postoperative setting: a worldwide survey of experts. Aliment Pharmacol Ther. 2011;33:707–713.CrossRefPubMed Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP. The use of azathioprine in Crohn’s disease during pregnancy and in the postoperative setting: a worldwide survey of experts. Aliment Pharmacol Ther. 2011;33:707–713.CrossRefPubMed
24.
Zurück zum Zitat Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.CrossRefPubMed Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.CrossRefPubMed
25.
Zurück zum Zitat Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–858.CrossRefPubMed Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847–858.CrossRefPubMed
26.
Zurück zum Zitat Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn’s disease. Clin Gastroenterol Hepatol. 2010;8:591–599.CrossRefPubMed Sorrentino D, Paviotti A, Terrosu G, Avellini C, Geraci M, Zarifi D. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn’s disease. Clin Gastroenterol Hepatol. 2010;8:591–599.CrossRefPubMed
29.
Zurück zum Zitat Tremaine WJ. Nine medico-legal pitfalls in inflammatory bowel disease in the United States. Curr Drug Targets. 2014;15:1039–1041.CrossRefPubMed Tremaine WJ. Nine medico-legal pitfalls in inflammatory bowel disease in the United States. Curr Drug Targets. 2014;15:1039–1041.CrossRefPubMed
Metadaten
Titel
Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey
verfasst von
Vu Q. Nguyen
Jessica L. Mays
Marissa Lang
Yingxing Wu
Themistocles Dassopoulos
Miguel Regueiro
Alan Moss
Deborah D. Proctor
Dario Sorrentino
Publikationsdatum
17.11.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4844-z

Weitere Artikel der Ausgabe 1/2018

Digestive Diseases and Sciences 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.